ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

10800	Companies
233652	Keywords
162321	Articles
124748	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 07/02/2026 at 08:00, 1 month 3 days ago

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€)
Abivax annonce l'exercice intégral de l'option de souscription d'ADS supplémentaires, atteignant un produit brut de 920 M$ (807 M€). Utilisation prévue pour financer commercialisation, R&D et besoins généraux

Biotechnologie Abivax Rectocolite Hémorragique Produit Brut Option De Souscription
PRESS RELEASE

published on 07/02/2026 at 08:00, 1 month 3 days ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax announces full exercise of underwriters' option to purchase additional ADSs, bringing gross proceeds of offering to $920M (€807M)

Biotechnology Abivax Capital Increase Underwriters ADSs
BRIEF

published on 07/01/2026 at 15:17, 1 month 3 days ago

Abivax resumes trading of its shares on Euronext Paris

Euronext Paris Biotechnology Actions Abivax Suspension
BRIEF

published on 07/01/2026 at 15:17, 1 month 3 days ago

Abivax reprend la cotation de ses actions sur Euronext Paris

Euronext Paris Biotechnologie Actions Abivax Suspension
BRIEF

published on 07/01/2026 at 15:17, 1 month 3 days ago

Abivax relance la cotation de ses actions sur Euronext Paris

Euronext Paris Abivax Actions Ordinaires Maladies Inflammatoires American Depositary Shares
BRIEF

published on 07/01/2026 at 15:17, 1 month 3 days ago

Abivax relaunches trading of its shares on Euronext Paris

Euronext Paris Ordinary Shares Abivax Inflammatory Diseases American Depositary Shares
PRESS RELEASE

published on 07/01/2026 at 15:12, 1 month 3 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Maladies Inflammatoires Traitements
PRESS RELEASE

published on 07/01/2026 at 15:12, 1 month 3 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. Abivax SA, société de biotechnologie au stade clinique, développe des traitements pour stabiliser la réponse immunitaire chez les patients

Euronext Paris Biotechnologie Abivax Actions Ordinaires Reprise Des Négociations
BRIEF

published on 07/01/2026 at 14:59, 1 month 3 days ago

Abivax Resumes Trading on Euronext Paris

Euronext Paris Biotechnology Abivax Ulcerative Colitis American Depositary Shares
BRIEF

published on 07/01/2026 at 14:59, 1 month 3 days ago

Abivax reprend sa cotation sur Euronext Paris

Euronext Paris Biotechnologie Abivax Rectocolite Hémorragique Actions De Dépôt Américaines

Accesswire

Published on 08/05/2026 at 02:10, 6 hours 24 minutes ago

Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance
Published on 08/04/2026 at 22:30, 10 hours 4 minutes ago

Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares
Published on 08/04/2026 at 22:00, 10 hours 34 minutes ago

Lockheed Martin and NioCorp Sign MOU
Published on 08/04/2026 at 17:00, 15 hours 34 minutes ago

Moderna annonce le début d'un essai clinique de phase 1 portant sur l’ARNm-1469, son vaccin expérimental contre l'ébolavirus de Bundibugyo
Published on 08/04/2026 at 16:25, 16 hours 9 minutes ago

ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026

View all ACCESSWIRE

EQS Group

Published on 08/05/2026 at 07:45, 48 minutes ago

Schaeffler AG expands partial retirement offer in Germany
Published on 08/05/2026 at 07:35, 58 minutes ago

Lenzing Reports Strongly Improved Half-Year Results and Accelerates Strategic Transformation Agenda
Published on 08/05/2026 at 07:30, 1 hour 3 minutes ago

Q2 2026: ElringKlinger maintains strong momentum in profitable growth and E-Mobility ramp-ups
Published on 08/05/2026 at 07:30, 1 hour 3 minutes ago

ZEAL continues its growth trajectory and reports highest first-half revenue in the company’s history
Published on 08/05/2026 at 07:30, 1 hour 3 minutes ago

voestalpine AG: voestalpine reports solid performance in the first quarter of 2026/27

Les Echos

Published on 08/04/2026 at 19:16, 13 hours 18 minutes ago

Covivio - 2026 Half-year financial report
Published on 08/04/2026 at 19:16, 13 hours 18 minutes ago

Covivio - Rapport financier semestriel 2026
Published on 08/04/2026 at 18:32, 14 hours 1 minute ago

Capital et droits de vote au 31 juillet 2026
Published on 08/04/2026 at 18:32, 14 hours 1 minute ago

Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 14 hours 49 minutes ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE